Evidence map›Paper›PMID 35194614›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Safety and Pharmacokinetics of Intranasally Administered Heparin.

Hannah M Harris, Katherine L Boyet, Hao Liu, Rohini Dwivedi, Nicole M Ashpole, Ritesh Tandon, Gene L Bidwell, Zhi Cheng, Lauren A Fassero, Christian S Yu and 8 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Hannah M HarrisDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Katherine L BoyetDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Hao LiuDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Rohini DwivediDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Nicole M AshpoleDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Ritesh TandonDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Gene L BidwellDepartment of Neurology, University of Mississippi Medical Center, Jackson, MS 39216.
Zhi ChengDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Lauren A FasseroDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216.
Christian S YuDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216.
Vitor H PominDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Dipanwita MitraDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216.
Kerri A HarrisonNational Center for Natural Products Research, University of Mississippi, Oxford, MS 38677.
Eric DahlNational Center for Natural Products Research, University of Mississippi, Oxford, MS 38677.
Bill J GurleyNational Center for Natural Products Research, University of Mississippi, Oxford, MS 38677.
Arun Kumar KothaDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, MS 38677.
Mahavir Bhupal ChouguleDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, MS 38677.
Joshua S SharpDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
University of Mississippi · USUniversity of Mississippi Medical Center · USJackson Memorial Hospital · USMercer University · US

Funding

Pilot Project ProgramP30GM122733 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI MAJUMDAR, SOUMYAJIT · 2018 to 2022
$5.3M
NIGMS NIH HHS P30 GM122733Shared Services Center NASA 80NSSC18K1603
6 · The paper itself

Abstract

purposeIntranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity.

methodsDouble-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 μg) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by

resultsUFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed.

conclusionsUFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 hours after dosing.

Identifiers

PMID35194614
PMCPMC8863150
OpenAlexW3181522248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.